Search research articles
Contact Us
Filters
Showing results (1-10 of 86) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1995
Docetaxel: current status and future prospects
E Eisenhauer
Cancer Chemotherapy and Pharmacology
|
February 28, 2001
A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity
L Seymour, E Eisenhauer
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2005
Confirmation of response in cancer clinical trials: a meaningless exercise?
P Therasse, E Eisenhauer
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 7, 2002
DNA methyltransferase inhibitors-state of the art
J Goffin, E Eisenhauer
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 8, 2001
Impact of new non-cytotoxics in the treatment of ovarian cancer
E Eisenhauer, J Dancey
Seminars in Oncology
|
April 16, 1998
Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer
F A Shepherd, E Eisenhauer
Seminars in Radiation Oncology
|
April 21, 1999
Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience
P Kirkbride, K Gelmon, E Eisenhauer
Journal of the National Cancer Institute
|
October 21, 1999
Re: Measure once or twice--does it really matter?
K James, E Eisenhauer, P Therasse
Journal of Biopharmaceutical Statistics
|
June 24, 1999
Multinomial phase II cancer trials incorporating response and early progression
B Zee, D Melnychuk, J Dancey, et al.
Canadian Journal of Physiology and Pharmacology
|
August 1, 1984
Some observations on vinca alkaloid and ethanol neurotoxicity using dissociated neuronal cultures
R J Riopelle, K E Dow, E Eisenhauer
Page
of 9
Search research articles
Search
Showing results (1-10 of 86) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1995
Docetaxel: current status and future prospects
E Eisenhauer
Cancer Chemotherapy and Pharmacology
|
February 28, 2001
A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity
L Seymour, E Eisenhauer
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2005
Confirmation of response in cancer clinical trials: a meaningless exercise?
P Therasse, E Eisenhauer
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 7, 2002
DNA methyltransferase inhibitors-state of the art
J Goffin, E Eisenhauer
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 8, 2001
Impact of new non-cytotoxics in the treatment of ovarian cancer
E Eisenhauer, J Dancey
Seminars in Oncology
|
April 16, 1998
Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer
F A Shepherd, E Eisenhauer
Seminars in Radiation Oncology
|
April 21, 1999
Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience
P Kirkbride, K Gelmon, E Eisenhauer
Journal of the National Cancer Institute
|
October 21, 1999
Re: Measure once or twice--does it really matter?
K James, E Eisenhauer, P Therasse
Journal of Biopharmaceutical Statistics
|
June 24, 1999
Multinomial phase II cancer trials incorporating response and early progression
B Zee, D Melnychuk, J Dancey, et al.
Canadian Journal of Physiology and Pharmacology
|
August 1, 1984
Some observations on vinca alkaloid and ethanol neurotoxicity using dissociated neuronal cultures
R J Riopelle, K E Dow, E Eisenhauer
Page
of 9